ARS Pharmaceuticals (SPRY) EBITDA Margin Growth (1y) (2023 - 2026)
ARS Pharmaceuticals (SPRY) EBITDA Margin Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1,049.00 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1,238.00 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -7.76 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -1,651.00 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2,002.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 29,091.00 |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 12,033.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12,033.00 |
| Mar 31, 2026 | 20,111.00 |
| Dec 31, 2025 | -20,214.00 |
| Sep 30, 2025 | 88,798.00 |
| Jun 30, 2025 | 276,505.00 |
| Jun 30, 2024 | 20.30 Mn |
| Jun 30, 2023 | -20.47 Mn |
| Mar 31, 2023 | -9.25 Mn |